<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02494297</url>
  </required_header>
  <id_info>
    <org_study_id>ZEG2014_04</org_study_id>
    <nct_id>NCT02494297</nct_id>
  </id_info>
  <brief_title>DUS on the Prescribing Indications for CPA/EE in 5 European Countries</brief_title>
  <official_title>Drug Utilization Study on the Prescribing Indications for Cyproterone Acetate and Ethinyl Estradiol in 5 European Countries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Epidemiology and Health Research, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for Epidemiology and Health Research, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to compile the reasons and specific indications for the prescription&#xD;
      of Cyproterone Acetate combined with Ethinyl Estradiol by Health Care Providers. The primary&#xD;
      objective of the study was to characterize the prescribing behaviors for Cyproterone Acetate&#xD;
      combined with Ethinyl Estradiol in 5 European countries (Austria, Czech Republic, France, the&#xD;
      Netherlands, and Spain), including:&#xD;
&#xD;
        -  prescription indications for Cyproterone Acetate combined with Ethinyl Estradiol&#xD;
&#xD;
        -  use of Cyproterone Acetate combined with Ethinyl Estradiol in accordance with the&#xD;
           updated label&#xD;
&#xD;
        -  concomitant use of Cyproterone Acetate combined with Ethinyl Estradiol and combined&#xD;
           hormonal contraceptives&#xD;
&#xD;
        -  second line treatment with Cyproterone Acetate combined with Ethinyl Estradiol for the&#xD;
           indication acne&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cyproterone acetate (CPA) 2mg, in combination with ethinyl estradiol (EE) 35mcg, is a&#xD;
      medicinal product currently indicated for the treatment of moderate to severe acne in women&#xD;
      of reproductive age. Due to the combination with ethinyl estradiol and the dosing, the&#xD;
      preparations also act as effective contraceptives.&#xD;
&#xD;
      In 2012, the French health authority conducted a national review of Cyproterone Acetate&#xD;
      combined with Ethinyl Estradiol and highlighted serious thromboembolic events and extensive&#xD;
      off-label use of these medicines as a contraceptive only. This triggered an Urgent Union&#xD;
      Procedure at the beginning of 2013. The European Medicines Agency's Pharmacovigilance Risk&#xD;
      Assessment Committee (PRAC) concluded that the benefits of Cyproterone Acetate combined with&#xD;
      Ethinyl Estradiol (cyproterone acetate 2mg / ethinyl estradiol 35mcg) outweigh the risks,&#xD;
      providing that several measures are taken to minimize the risk of thromboembolism. These&#xD;
      medicines should be used solely for the treatment of moderate to severe acne related to&#xD;
      androgen sensitivity and/or hirsutism in women of reproductive age. Since Cyproterone Acetate&#xD;
      combined with Ethinyl Estradiol acts as a hormonal contraceptive, women should not take these&#xD;
      medicines in combination with hormonal contraceptives. As one of the risk minimization&#xD;
      measures, the Market Authorization Holders were required to conduct a number of studies&#xD;
      including this drug utilization survey.&#xD;
&#xD;
      This study was a multi-national, cross sectional, prospective, non-interventional, drug&#xD;
      utilization study conducted in 5 countries. Study participants were recruited by a network of&#xD;
      health care professionals. Physicians collected information from study participants based on&#xD;
      questionnaires. This was a one-time survey with no follow-up.&#xD;
&#xD;
      Bayer initiated this study and supported it by an unconditional grant to ZEG. Bayer was not&#xD;
      actively involved in the study conduct.&#xD;
&#xD;
      Prolongation of recruitment:&#xD;
&#xD;
      At the beginning of May 2016 the recruitment was finished in 4 of the 5 European countries in&#xD;
      which the study was conducted (Austria, Czech Republic, The Netherlands, and Spain). At that&#xD;
      point in time, only few patients were enrolled in France because of a delayed recruitment&#xD;
      start. Therefore, it was agreed to extend the recruitment phase in France until 31st October&#xD;
      2016, in order to ensure that information on the use of Cyproterone Acetate (combined with&#xD;
      Ethinyl Estradiol) would be collected from all participating countries.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 6, 2015</start_date>
  <completion_date type="Actual">October 31, 2016</completion_date>
  <primary_completion_date type="Actual">October 31, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Drug Utilization Pattern of Cyproterone Acetate and Ethinyl Estradiol</measure>
    <time_frame>within 18 months</time_frame>
    <description>Information was obtained from doctors prescribing CPA/EE. Categories in the Outcom Measure Data Table below are based on current disease status.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1597</enrollment>
  <condition>Hirsutism</condition>
  <condition>Androgenetic Alopecia</condition>
  <condition>Severe Anemia</condition>
  <condition>Seborrhea</condition>
  <condition>PCOS</condition>
  <arm_group>
    <arm_group_label>Cyproterone Acetate and Ethinyl Estradiol</arm_group_label>
    <description>Users of Diane 35 (EE/CPA, BAY86-5264)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Women who are prescribed Cyproterone Acetate combined with Ethinyl Estradiol during the&#xD;
        study period&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women who are prescribed Cyproterone Acetate combined with Ethinyl Estradiol during&#xD;
             the study period&#xD;
&#xD;
          -  Women who are willing to participate in the drug utilization study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are not willing to sign the informed consent&#xD;
&#xD;
          -  Women with a language barrier&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaas Heinemann, PhD, MD, MSc, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Epidemiology and Health Research Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center of Epidemiology and Health Research</name>
      <address>
        <city>Berlin</city>
        <zip>10115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_BSP_7261&amp;studyid=2078&amp;filename=17194_Study%20Synopsis_CTP.pdf</url>
    <description>Clinical Study Synopsis from Bayer AG</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 8, 2015</study_first_submitted>
  <study_first_submitted_qc>July 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2015</study_first_posted>
  <results_first_submitted>November 7, 2018</results_first_submitted>
  <results_first_submitted_qc>August 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 27, 2021</results_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Hirsutism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment from March-2015 to 11-May-2016 in Austria, Czech Republic, The Netherlands and Spain; recruitment in France from January-2016 to 31-October-2016, due to late start. Recruitment was conducted by gynecologists, dermatologists and general practitioners.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cyproterone Acetate and Ethinyl Estradiol</title>
          <description>Users of Diane 35 (EE/CPA, BAY86-5264), uncontrolled, single armed drug utilization study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1597"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1597">As there was no Follow-Up in this study, participation equals completion</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cyproterone Acetate and Ethinyl Estradiol</title>
          <description>Users of Diane 35 (EE/CPA, BAY86-5264), uncontrolled, single armed drug utilization study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1597"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.0" spread="7.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>18-24 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="647"/>
                  </measurement_list>
                </category>
                <category>
                  <title>25-34 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="533"/>
                  </measurement_list>
                </category>
                <category>
                  <title>35-49 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=50 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1597"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Drug Utilization Pattern of Cyproterone Acetate and Ethinyl Estradiol</title>
        <description>Information was obtained from doctors prescribing CPA/EE. Categories in the Outcom Measure Data Table below are based on current disease status.</description>
        <time_frame>within 18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cyproterone Acetate and Ethinyl Estradiol</title>
            <description>Users of Diane 35 (EE/CPA, BAY86-5264), uncontrolled, single armed drug utilization study</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Utilization Pattern of Cyproterone Acetate and Ethinyl Estradiol</title>
          <description>Information was obtained from doctors prescribing CPA/EE. Categories in the Outcom Measure Data Table below are based on current disease status.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1597"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Moderate or severe acne (without hirsutism)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="594"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Acne with hirsutism</title>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hirsutism without acne</title>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other androgenic diseases and contraception</title>
                  <measurement_list>
                    <measurement group_id="O1" value="769"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were not monitored in this study, which was a non-interventional observational cross sectional study on drug utilization patterns that exclusively obtained information at the time point of prescription. There were no questions that could generate adverse events (AEs) and no follow-up questionnaires.</time_frame>
      <desc>Since this was a drug utilization study, exclusively obtaining information at the time of prescription, no adverse events were reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cyproterone Acetate and Ethinyl Estradiol</title>
          <description>Users of Diane 35 (EE/CPA, BAY86-5264), uncontrolled, single armed drug utilization study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The data cannot indicate a difference in prescribing habits between participating and non-participating physicians. The information about previous treatments of acne is likely to be incomplete because of recall bias.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Klaas Heinemann</name_or_title>
      <organization>Center for Epidemiology and Health Research, Germany</organization>
      <phone>0049 (0) 30 945 101 20</phone>
      <email>k.heinemann@zeg-berlin.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

